...
首页> 外文期刊>Thyroid: official journal of the American Thyroid Association >Blockade of costimulation between T cells and antigen-presenting cells: an approach to suppress murine Graves' disease induced using thyrotropin receptor-expressing adenovirus.
【24h】

Blockade of costimulation between T cells and antigen-presenting cells: an approach to suppress murine Graves' disease induced using thyrotropin receptor-expressing adenovirus.

机译:阻断T细胞和抗原呈递细胞之间的共刺激:抑制表达促甲状腺激素受体的腺病毒诱导的鼠Graves病的方法。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Immune responses require costimulatory interactions between molecules on antigen-presenting cells and T cells: CD40 binding to CD40 ligand and B7 binding to CD28. Graves' hyperthyroidism is induced in BALB/c mice by immunization with thyrotropin receptor (TSHR) A-subunit adenovirus (Ad-A-subunit). We attempted to modulate Ad-A-subunit-induced Graves' disease using adenoviruses expressing costimulation "decoys": CD40-IgG-Fc (CD40-Ig) to block CD40:CD40-ligand interactions and CTLA4-Fc (CTLA4-Ig) to prevent B7:CD28 binding. OUTCOME: Unexpectedly, coimmunizing mice with Ad-A-subunit and excess control adenovirus (1:10 Ad-A-subunit:Ad-control) reduced TSHR antibody levels (thyrotropin binding inhibition [TBI]). Furthermore, only 15% of mice developed hyperthyroidism versus 75% using the same Ad-A-subunit dose (10(8) particles) without Ad-control. This effect was related to the dose of control adenovirus but not to the adenovirus insert, the timing or immunization site. Increasing the Ad-subunit dose (10(9) particles) and decreasing the control adenovirus dose (10:1 Ad-A-subunit:Ad-control) induced high TBI levels and 80% of mice were hyperthyroid. Coimmunization with Ad-CD40-Ig (but not Ad-CTLA4-Ig) reduced the incidence of hyperthyroidism to 40%. CONCLUSIONS: Using appropriate controls and adenovirus ratios, our data suggest the importance of CD40:CD40-ligand interactions for inducing Graves' hyperthyroidism by Ad-A-subunit. Furthermore, our observations emphasize the potential pitfalls of non-specific inhibition by coimmunization with two adenovirus species.
机译:目的:免疫反应需要抗原呈递细胞和T细胞上分子之间的共刺激相互作用:CD40与CD40配体结合,B7与CD28结合。通过用促甲状腺激素受体(TSHR)A亚基腺病毒(Ad-A亚基)免疫在BALB / c小鼠中诱导Graves甲状腺功能亢进。我们尝试使用表达共刺激“诱饵”的腺病毒调节Ad-A亚基诱导的Graves病:CD40-IgG-Fc(CD40-Ig)阻断CD40:CD40-配体相互作用和CTLA4-Fc(CTLA4-Ig)防止B7:CD28绑定。结果:出乎意料的是,用Ad-A亚基和过量对照腺病毒(1:10 Ad-A亚基:Ad-control)对小鼠进行免疫接种可降低TSHR抗体水平(促甲状腺激素结合抑制[TBI])。此外,只有15%的小鼠发展为甲状腺功能亢进,而使用相同的Ad-A亚基剂量(10(8)颗粒)而不使用Ad对照的小鼠为75%。该作用与对照腺病毒的剂量有关,但与腺病毒插入片段,时间或免疫部位无关。增加Ad-亚基剂量(10(9)颗粒)和降低对照腺病毒剂量(10:1 Ad-A-亚基:Ad-control)可诱导高TBI水平,且80%的小鼠甲状腺功能亢进。与Ad-CD40-Ig(而不是Ad-CTLA4-Ig)共免疫可将甲状腺功能亢进症的发生率降至40%。结论:使用适当的对照和腺病毒比率,我们的数据表明CD40:CD40-配体相互作用对于通过Ad-A-亚基诱导格雷夫斯甲状腺功能亢进症的重要性。此外,我们的观察结果强调了通过与两种腺病毒共免疫进行非特异性抑制的潜在陷阱。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号